GlassScriptPhysician profile
Heather M Schibi
NPI 1134576226
$1,466.74
in general payments reported to CMS, 2019-2025
19 companies · $809 in 2025
The $809 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $70.73 · 2022: $17.96 · 2023: $36.94 · 2024: $532 · 2025: $809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,378.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $368.22 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $243.72 | 2024-2025 | Airsupra, Breztri, Flumist Quadrivalent |
| Pfizer INC. | $189.82 | 2023-2025 | |
| Biotronik Nro, INC. | $135.40 | 2025 | Prospera |
| Viiv Healthcare Company | $123.97 | 2025 | Apretude |
| Merck Sharp & Dohme LLC | $75.59 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Biohaven Pharmaceuticals, INC. | $51.32 | 2021 | |
| Sanofi-Aventis U.S. LLC | $42.22 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.09 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $27.92 | 2024 | Gattex |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.59 | 2024 | Rexulti |
| Exact Sciences Corporation | $22.42 | 2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $20.93 | 2025 | Mounjaro |
| Exeltis, USA INC. | $20.86 | 2025 | Slynd |
| Corcept Therapeutics | $20.14 | 2025 | Korlym |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $19.41 | 2021 | |
| Janssen Pharmaceuticals, INC | $18.83 | 2025 | Invega Sustenna |
| Novo Nordisk INC | $16.55 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.74 | 2024 | Tradjenta, Jardiance, Synjardy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Schibi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.